Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London afternoon: Stocks back on the climb

Mon, 11th Jan 2010 14:16

Leading shares, which had been surrendering early gains at the end of the morning, picked up again over the lunch time session, helped by expectations of a firm start by Wall Street.In the absence of much in the way of corporate events to attract attention, traders have been focused on broker notes. Oil company Cairn Energy remains the best performer after positive noises from Citigroup. The broker says that fast-tracking the multi-well exploration drilling programme in Greenland has made the group its preferred play on frontier exploration in 2010. Dana is its value play while Tullow could be the most exciting story over the first quarter.Miners are going well on another set of trade figures from China. Exports rose by 17.7%, but imports, largely raw materials including copper, jumped by 55%. Lonmin, Rio Tinto, Kazakhmys and Xstrata are leading the miners higher. Silver miner Fresnillo is little changed, however, after it dropped out of the race for Canadian mining company Canplats Resources.Barclays has received its third upbeat broker note in less than a week. This time it is Citigroup that reckons the bank is cheap, adding that the market is applying too low a rating to Barclays' earnings. Citigroup's target price is 413p, implying 30% upside.Property groups Land Securities and British Land are higher after the former was added to Goldman Sachs' 'conviction buy' list. Segro, which also updated on trading today, is higher after Goldman upgraded its rating on the stock to 'neutral'. Separately, Inès Reinman, Segro's head of Continental Europe, has resigned from the industrial property group barely a year she was promoted to the board. "Current trading and market conditions are in line with our expectations at the time of our Interim Management Statement issued on 5 November 2009," chief executive Ian Coull added.SABMiller is lower after it pulled out of the race to buy the Femsa stable of beer brands leaving the way clear for rival brewer Heineken.Cash strapped plumbers merchant Wolseley is to raise just under £24m from the sale of its Irish businesses. WIBHM, a company backed by private investor, is paying €26.5m for Wolseley Ireland Holdings Limited. The exceptional loss on disposal, excluding currency impacts, is expected to be around €55m (£50m).Online gaming group PartyGaming has tied up an an exclusive, five-year agreement with state-controlled Danske Spil to provide an online gaming platform for poker and casino games in Denmark. Outdoor clothing retailer Blacks Leisure said it is mulling a possible equity fundraising in the first quarter to raise between £15m and £20m depending on investor demand. It hopes to roll out new stores, having closed 87 loss-making outlets in the fourth quarter of 2009. It said trading in the ongoing stores was very healthy with like-for-like sales increasing by 12.0% in the half year ended 7 JanuaryThe US Navy has awarded defence and aerospace group Cobham a contract worth up to $11.5m for the UK group. Cobham has won the Band 5/6 TWT (Travelling-wave Tube) Replacement Module Assembly (TRMA) development contract.Stem cell therapy group ReNeuron said it is on track to start human trials of its flagship treatment ReN001 for disabled stroke patients in the first quarter of this year.EMED Mining's quest to reopen the Rio Tinto mine in Spain moved a step closer following recent court rulings deemed favourable to the company. The cases all related to objections by previous stakeholders in the mine.
More News
9 Apr 2019 10:55

ReNeuron Signs Licence Deal For CTX, hRPC Cell Programmes In China

LONDON (Alliance News) - ReNeuron Group PLC on Tuesday said it has signed an exclusive licence agreement for the development, manufacture and commercialisation of its CTX and hRPC cell therapy in

Read more
4 Apr 2019 14:19

ReNeuron upbeat on progress in hRPC study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.

Read more
4 Apr 2019 10:32

ReNeuron Shares Rise On Positive Data From Blindness Treatment Trial

LONDON (Alliance News) - Shares rose in ReNeuron Group PLC on Thursday after it reported positive efficacy in a phase one/two clinical trial of its hRPC cell therapy candidate for treating in the

Read more
18 Mar 2019 11:42

ReNeuron Group Starts Dosing Of Second Cohort In hRPC Study

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it started dosing of the second cohort of patients in a phase II study of its hRPC cell therapy candidate in the blindness-causing of in

Read more
18 Mar 2019 11:33

ReNeuron Group begins dosing second cohort in hRPC study

(Sharecast News) - Cell-based therapeutics company ReNeuron Group updated the market on progress with the ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more
20 Feb 2019 09:47

ReNeuron Reports Positive Preliminary Data In US Retinal Trial

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday reported "significant improvement in vision" in the trial of its hRPC cell therapy candidate for retinal disease.ReNeuron

Read more
20 Feb 2019 08:21

ReNeuron storms on 'exciting' eye disease trial success

(Sharecast News) - ReNeuron Group bounded upward on Wednesday after reporting that its cell-based therapy is showing signs that it can improve the sight of patients suffering from retinitis pigmentosa, which causes blindness.

Read more
31 Jan 2019 09:55

ReNeuron upbeat on data around ease of exosome manufacture

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that new data relating to the manufacturing scale-up of its GMP produced, CTX-derived exosomes was being presented at a US forum on the manufacture of cell and gene therapies.

Read more
24 Jan 2019 12:16

ReNeuron Group Reports First Enrolled Patient In Stroke Clinical Trial

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it enrolled the first patient in its US Phase IIb clinical study of CTX stem cell therapy for stroke disability.The study is a 6

Read more
24 Jan 2019 09:46

First patient dosed in latest ReNeuron study of CTX cell therapy

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that the first patient has been treated in the US Phase IIb clinical study of its 'CTX' cell therapy candidate for stroke disability.

Read more
4 Jan 2019 07:59

ReNeuron Group to collaborate with unnamed US biopharmaceutical firm

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has signed a collaboration agreement with an unnamed US-based biopharmaceutical company to explore the use of its exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy, it announced on Friday.

Read more
14 Dec 2018 12:07

ReNeuron narrows losses as development programmes continue

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group issued its interim results for the six months ended 30 September on Friday, reporting a reduced loss for the period of £5.32m, from £9.57m year-on-year.

Read more
7 Dec 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 10 December Photo-Me InternationalHalf Year ResultsHollywood Bowl GroupFull Year

Read more
18 Oct 2018 12:42

Reneuron's stem cell technology could produce cancer-combating cells

(Sharecast News) - New data from a study by Reneuron has encouraged the company that its stem cell technology could be adapted to specifically attack cancerous cells.

Read more
18 Oct 2018 10:54

ReNeuron Reports New Positive Data Relating To CTX Stem Cell Platform

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said its CTX stem cell therapy candidate can be successfully re-programmed to a pluripotent state.Pluripotent state is an embryonic a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.